PULMATRIX INC (PULM) Stock Price, Quote, News and Overview
NASDAQ:PULM - Nasdaq - US74584P3010 - Common Stock - Currency: USD
PULM Quote, Performance and Key Statistics
8.92
-0.09 (-1%)
The current stock price of PULM is 8.92 USD. In the past month the price increased by 29.46%. In the past year, price increased by 357.44%.
PULM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About PULM
Company Profile
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 22 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Company Info
PULMATRIX INC
945 Concord Street, Suite 1217
Framingham MASSACHUSETTS 02421 US
CEO: Teofilo Raad
Employees: 22
Company Website: https://www.pulmatrix.com/
Investor Relations: http://ir.pulmatrix.com/
Phone: 18883554440
PULMATRIX INC / PULM FAQ
What is the stock price of PULMATRIX INC today?
The current stock price of PULM is 8.92 USD. The price decreased by -1% in the last trading session.
What is the ticker symbol for PULMATRIX INC stock?
The exchange symbol of PULMATRIX INC is PULM and it is listed on the Nasdaq exchange.
On which exchange is PULM stock listed?
PULM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PULMATRIX INC stock?
7 analysts have analysed PULM and the average price target is 10.2 USD. This implies a price increase of 14.35% is expected in the next year compared to the current price of 8.92. Check the PULMATRIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PULMATRIX INC worth?
PULMATRIX INC (PULM) has a market capitalization of 32.56M USD. This makes PULM a Nano Cap stock.
How many employees does PULMATRIX INC have?
PULMATRIX INC (PULM) currently has 22 employees.
What are the support and resistance levels for PULMATRIX INC (PULM) stock?
PULMATRIX INC (PULM) has a support level at 6.12. Check the full technical report for a detailed analysis of PULM support and resistance levels.
Is PULMATRIX INC (PULM) expected to grow?
The Revenue of PULMATRIX INC (PULM) is expected to grow by 1% in the next year. Check the estimates tab for more information on the PULM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PULMATRIX INC (PULM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PULM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PULM, evaluating the profitability, health, valuation and growth aspects
- PULMATRIX INC (PULM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PULMATRIX INC (PULM) Sales and EPS estimates to see what analysts future expectations are.
- PULMATRIX INC (PULM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PULMATRIX INC (PULM) Insider and Institutional Ownership to learn about the owners and their transactions.
- PULMATRIX INC (PULM) Stock Chart to make your own analysis
- PULMATRIX INC (PULM) Latest news and press-releases to stay up to date.
Does PULMATRIX INC (PULM) stock pay dividends?
PULM does not pay a dividend.
When does PULMATRIX INC (PULM) report earnings?
PULMATRIX INC (PULM) will report earnings on 2025-03-26, before the market open.
What is the Price/Earnings (PE) ratio of PULMATRIX INC (PULM)?
PULMATRIX INC (PULM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.86).
What is the Short Interest ratio of PULMATRIX INC (PULM) stock?
The outstanding short interest for PULMATRIX INC (PULM) is 1.45% of its float. Check the ownership tab for more information on the PULM short interest.
PULM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PULM. When comparing the yearly performance of all stocks, PULM is one of the better performing stocks in the market, outperforming 98.86% of all stocks.
PULM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PULM. PULM has a great financial health rating, but its profitability evaluates not so good.
PULM Financial Highlights
Over the last trailing twelve months PULM reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS increased by 29.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.89% | ||
| ROE | -88.42% | ||
| Debt/Equity | 0 |
PULM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PULM. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -18.91% and a revenue growth 1% for PULM